Gwynne Dyer is a Canadian-born independent journalist whose column is published in more than 175 papers in 45 countries.

By Gwynne Dyer

Nine of the world’s biggest pharmaceutical companies have just promised not to apply for regulatory approval for any new Covid-19 vaccine before it has gone through all three phases of clinical study. Why would they do such a thing?

Obviously, it’s the perception that other players in the same market may be cutting corners.

Usually the Trump administration’s actions are viewed with weary resignation by the rest of the world, but it would still be a very big deal if the United States started distributing a vaccine that had not been properly tested. Yet the signs are that that’s just what is going to happen.

Last month at the Republican national convention Donald Trump told the delegates and the country: “We are developing life-saving therapies, and will produce a vaccine before the end of the year, or maybe even sooner.”

On 4 September, the US government’s Centers for Disease Control and Prevention (CDC) told American health officials that “limited Covid-19 vaccine doses may be available by early November 2020.”

More specifically, the CDC urged state authorities to consider “waiving requirements” and grant permits to McKesson Corporation so they can start distributing a vaccine by 1 November.

You don’t need a weatherman to know which way the wind blows. The presidential election is on 3 November, two days later: that’s long enough for the glad news to get around and floating voters to be swayed in favour of Trump, but too short for any defects in the rushed vaccine to come to light.

Donald Trump is going to liberate Americans from the curse of Covid just before the election. If the vaccine’s miraculous properties subsequently fade, even if it kills large numbers of people, that won’t matter. The votes will have been counted, and Trump will be back in office for another four years. That, at least, is the scenario that is currently envisaged by the people around Trump.

The nine pharmaceutical majors who felt the need to issue a “historic pledge” to uphold scientific and ethical standards were doubtless driven by this scenario.

Even if there really has been an American breakthrough, they would still have to cope with the public’s suspicion that Trump is cheating – and the mistrust that will also attach to any other early vaccines.

It is possible that the vaccine that Trump is about to unleash on the American public really does work and is safe. It would be a historic first – having a Covid vaccine ready for general use by next June or July would normally be seen as a remarkable achievement – but miracles do happen.

The problem is that they don’t happen often, and if the full testing regime is not followed, you don’t know if this is one of those times.

It’s only because the AstraZeneca/Oxford University vaccine was going through the full third phase of tests, involving tens of thousands of individuals and many months of testing, that they spotted a bad reaction requiring hospitalisation on Wednesday and paused the tests. The American miracle vaccine will only start third-stage tests at the same time that it is made generally available.

Pauses like AstraZeneca/Oxford University’s happen often in the development of a vaccine, and the pause will probably only be temporary. But even a very low-frequency bad reaction can be a mass killer when tens of millions of people are being vaccinated, and these are not desperately sick people willing to risk anything for a cure. They are people in good health, and you mustn’t kill them.